• Zencore's proprietary CLD platform generates stable high yield single clones in 3 months, while traditional CLD process takes 5~6 months

• Replace traditional ELISA with ForteBio Octet has greatly improved the efficiency and accuracy for cell line screening.

  

• A high throughput analytical method is implemented to identify cell lines with the high titer and good quality for BsAbs CLD.

• Host cell licensure for global R&D and commercialization 

• Cell line construction process documented compliant with global regulations

• Supporting global regulatory submission

• Complete host cell traceability

• Industrial standard monoclonality guaranteed

Single cell printer is used for efficient single cell screening, the monoclonal selection rate is up to 90%, a 5 fold improvement over traditional limited dilution method.

Combined with continuous imaging technology of cell culture 96-well plate, we can monitor the growth and division process of single gram cells and provide complete monoclonal traceability. 

• The median titer of mAb was above 5.0 g/L, and the highest titer achieved at 15.0 g/L

• The median titer of bispecific antibody was above 5.0 g/L, and the highest titer achieved at 9.0 g/L
  

• The average titer of recombinant protein was above 5.0g/L , and the highest titer achieved at 7.0 g/L

• Fully adapted ATCC CHO-K1 cells with global licensure for  R&D and commercial production

• Introducing ECACC CHO-K1 cells
  

• Accepting customer-specified host cell platforms development